官方服务：
资源简介：
Collection of samples and data across the following diseases: Malignant lymphoma (disorder)
应用场景：
创建时间：
2021-02-22
相关数据集
Tislelizumab and radiotherapy in low-risk early-stage extranodal nasal-type NK/T-cell lymphoma: A Phase II Study Protocol - supplementary material
Supplementary table 1 CLCG-NKT-2101 Flowchart for assessment of treatment and follow up phase
DataCite Commons2024-05-15 更新100
Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma: supplementary tables
Aim: To evaluate trials of systemic therapies in transplant-ineligible or -experienced, relapsed/refractory diffuse large-B cell lymphoma and the impact of patient characteristics on overall response
DataCite Commons2022-11-23 更新50
Phase 1 study of inotuzumab ozogamicin combined with r-gdp for the treatment of patients with relapsed/refractory cd22+ b-cell non-hodgkin lymphoma
Objective : To evaluate safety, tolerability, and preliminary activity of inotuzumab ozogamicin (InO) plus rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) in patients with relapsed/
Taylor & Francis Group2019-09-06 更新10
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis.. Homo sapiens
Large B cell lymphoma is recognized as a heterogeneous disease those relapse may occur in up to 30-40% of the patients. Therefore, relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) represe
NIAID Data Ecosystem70
A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus rituximab in adult Asia Pacific region patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or
DataCite Commons2025-02-10 更新10
